Key highlights
- Launched SimpleScreen Lung, a blood-based test for adults aged 50-80 with a 20 pack-year smoking history
- Introduced integrated screening allowing concurrent lung and colorectal cancer (CRC) detection from one draw
- Clinical validation showed 85% sensitivity at 50% specificity for the lung screening component
- Achieved 99.8% negative predictive value (NPV), meaning only 2 in 1,000 negative results expect cancer
- Targets the 80% of eligible lung screening candidates not currently up to date with standard imaging
Strategic Launch of Dual-Cancer Screening
Freenome has officially launched SimpleScreen Lung, a laboratory-developed test designed for adults at high risk due to their smoking history. This product debut includes a unique clinical offering that enables patients to be screened for both lung and colorectal cancer (CRC) using two independently validated tests from a single blood draw. The lung test targets individuals aged 50 to 80 with a 20 pack-year smoking history, including former smokers who have already quit. By consolidating these screenings, Freenome aims to simplify the diagnostic process for the 10 million Americans eligible for lung screening and the 60 million currently behind on CRC screening.
Clinical Performance and Adherence Goals
- SimpleScreen Lung demonstrated 85% sensitivity at 50% specificity in an independent cohort study
- The test achieved sensitivity of 82% for stage I and 75% for stage II lung cancer cases
- Clinical validation for the CRC component showed 81% sensitivity and 90% specificity for advanced neoplasia
- The high 99.8% NPV for lung cancer provides a critical metric for ruling out the disease in non-symptomatic patients
- Product design aligns with the 2023 American Cancer Society lung cancer screening guideline updates
Corporate and Financial Background
This product expansion follows a period of significant corporate development for Freenome. In July 2026, the company completed its business combination with Perceptive Capital Solutions Corp, listing on the Nasdaq and securing over $310 million in funding. The company also recently established a $100 million commercialization partnership with Abbott for its FDA-approved SimpleScreen CRC test. With a market capitalization of $1.35 billion and revenue of $30.4 million, Freenome is focused on scaling its Personalized Cancer Detection portfolio. The company is scheduled to release its third-quarter 2026 financial results on November 10, providing further insight into its commercial progress and cash runway.
Down 19.7% since our story on 20 Oct: $12.57 when we broke it → $10.09 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $12.57 |
|---|---|
| 20 Oct | $14.06 |
| 21 Oct | $14.01 |
| 22 Oct | $13.10 |
| 23 Oct | $12.77 |
| 26 Oct | $12.72 |
| 27 Oct | $13.04 |
| 28 Oct | $13.44 |
| 29 Oct | $12.86 |
| 30 Oct | $12.48 |
| 2 Nov | $11.61 |
| 3 Nov | $11.47 |
| 4 Nov | $11.30 |
| 5 Nov | $10.47 |
| 6 Nov | $10.18 |
| 9 Nov | $10.57 |
| 10 Nov | $10.77 |
| 11 Nov | $11.56 |
| 12 Nov | $10.61 |
| 13 Nov | $10.41 |
| 16 Nov | $10.09 |
Medical Perspective on Screening Access
“A blood-based test adds a practical option to our patient conversations and helps us make progress toward our goal of connecting more eligible people with screening and getting them to take the next step.”
| Date | Announcement | Amount |
|---|---|---|
| 15 Oct 2026 | Announcement of third quarter 2026 financial results release and conference call dateSource: markets.businessinsider.com | – |
| 11 Oct 2026 | Presentation of clinical validation data for updated CRC screening test at ACG 2026Source: freenome.com | – |
| 12 Aug 2026 | SimpleScreen Lung screening test granted FDA Breakthrough Device designationSource: freenome.com | – |
| 27 Jul 2026 | FDA approval of SimpleScreen CRC screening test and Abbott commercialization partnershipSource: SEC filing | $100.0 Million |
| 20 Jul 2026 | Completion of business combination with Perceptive Capital Solutions Corp and Nasdaq listingSource: wsgr.com | $310.3 Million |
Management commentary
“Lung cancer screening can save lives, but its potential depends on reaching people who are eligible.”
| Share price | $12.57 |
|---|---|
| Market cap | $1.4B |
| Revenue (annual) | $30M |
| 1-month price change | -22.84% |
| Sector | HealthcareDiagnostics & Research |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Freenome, Inc. announcing the launch of the SimpleScreen Lung test and integrated dual-cancer screening offering.
Track Freenome, Inc. live
Get the next Freenome, Inc. SEC filing seconds after it lands.